InvestorsHub Logo
Followers 59
Posts 4696
Boards Moderated 0
Alias Born 04/27/2009

Re: None

Sunday, 04/11/2021 12:36:15 AM

Sunday, April 11, 2021 12:36:15 AM

Post# of 118379
Can someone dig up anything on this guy?

"We have identified a handful of compounds representing three different structural classes that inhibit NR2F6 in our primary screening assay," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.

https://www.prnewswire.com/news-releases/regen-biopharma-inc-reports-success-of-its-nr2f6-small-molecule-screening-program-for-treating-autoimmune-diseases-868309898.html